Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

Sperl, Jan; Horvath, Gabor; Halota, Waldemar; Arenas Ruiz-Tapiador, Juan; Streinu-Cercel, Anca; Jancoriene, Ligita; Werling, Klara; Kileng, Hege; KÖKLÜ, SEYFETTİN; Gerstoft, Jan; Urbanek, Petr; Flisiak, Robert; Leiva, Rafael; Kazenaite, Edita; Prinzing, Renate; Patel, Sushma; Qiu, Jingjun; Asante-Appiah, Ernest; Wahl, Janice; Bach-Yen Nguyen, Bach-Yen; Barr, Eliav; Platt, Heather

doi:10.1016/j.jhep.2016.07.050

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

Sperl J., Horvath G., Halota W., Arenas Ruiz-Tapiador J., Streinu-Cercel A., Jancoriene L., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.65, sa.6, ss.1112-1119, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.jhep.2016.07.050
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1112-1119
Hacettepe Üniversitesi Adresli: Evet

Özet

Background & Aims: Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) in patients with HCV infection.